Form 4: Avanos Medical Interim CEO Michael Greiner Reports Share Transactions
SEC Form 4 Filing
Interim CEO Michael Greiner reports the vesting and subsequent transactions of performance-based and time-based restricted share units, along with tax withholding obligations.
Summary
- On March 4, 2025, Michael Greiner, Interim CEO of Avanos Medical, reported transactions related to vested restricted share units.
- 12,149 performance-based restricted share units (PRSUs) awarded on March 4, 2022, vested on March 4, 2025.
- Shares were surrendered to the issuer to satisfy tax withholding obligations upon the vesting of both PRSUs and time-based restricted share units (TRSUs).
- Specifically, 6,048 shares were surrendered related to the PRSU vesting and 4,642 shares were surrendered related to the TRSU vesting.
- Greiner also acquired 666 shares on December 31, 2024, and 522 shares on June 30, 2024, under the company's Employee Stock Purchase Plan.
- Following these transactions, Greiner beneficially owns 203,545 shares of Avanos Medical common stock.
Sentiment
Score: 6
Explanation: The document primarily reflects routine transactions related to executive compensation. The vesting of shares is generally a positive sign, but the subsequent tax withholding is a neutral event. Overall, the sentiment is moderately positive.
Positives
- The vesting of restricted share units indicates that performance metrics were likely met, which is a positive signal.
- Participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors monitor these filings to gauge management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- Shareholders may view the vesting of restricted share units as a sign of management's commitment and alignment with company performance.
- The transactions have a minor impact on the overall share structure of the company.
Key Dates
| Date | Description |
|---|---|
| 2022-03-04 | Date PRSUs and TRSUs were awarded to the Reporting Person |
| 2024-06-30 | Date of share acquisition under the Employee Stock Purchase Plan |
| 2024-12-31 | Date of share acquisition under the Employee Stock Purchase Plan |
| 2025-03-04 | Date of earliest transaction; vesting date of PRSUs and TRSUs |
| 2025-03-06 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.